These data further support the notion that GOLPH3L up-regulation promotes ovarian cancer aggressiveness and activation of the NF-κB signaling pathway, which may lead to a poor clinical outcome for patients with ovarian cancer. The gene discussed is GOLPH3L; the disease is ovarian cancer.